Board of Directors

Stephen Albert Johnston, Director, CEO

Anna D. Barker, Ph.D.

Dr. Barker is co-director of Complex Adaptive Systems at Arizona State University (ASU), which serves as an organizing construct to understand and solve multidimensional problems in the biomedical sciences and biomedicine. She develops knowledge networks that leverage convergent knowledge in the biological and physical sciences, innovative teams, and novel funding approaches to better prevent and treat acute and chronic diseases. Prior to

joining ASU, Dr. Barker served for several years as the deputy director of the National Cancer Institute(NCI) where she developed and implemented strategic transdisciplinary programs, including:  the Nanotechnology Alliance for Cancer; The Cancer Genome Atlas (TCGA) (in collaboration with the National Human Genome Research Institute); the Clinical Proteomics Technologies Initiative for Cancer; the Physical Sciences-Oncology Centers; and national initiatives in biospecimen best practices and bioinformatics. All of these programs emphasize the synergy of large- scale and individual-initiated research; precompetitive collaborations, publically available data and clinical translation to more effectively detect, prevent and treat cancer. She also oversaw the NCI’s international cancer research programs, including pilot programs in Latin America and China.  Dr. Barker was the founding co-chair of the NCI-FDA Interagency Task Force, founding co-chair of the Cancer Steering Committee of the Foundation for the National Institutes of Health (FNIH) Biomarker Consortium, and founding director of the NBDA. She has a long history in research and in the leadership and management of research and development in the academic, nonprofit, and private sectors. Dr. Barker served as a senior scientist and subsequently as a senior executive at Battelle Memorial Institute for 18 years and cofounded and served as the CEO of a public biotechnology drug development company. She has received a number of awards for her work in support of cancer research, cancer patients, professional and advocacy organizations, and the ongoing national effort to prevent and cure cancer. Dr. Barker’s research interests include complex adaptive systems, evolutionary medicine and free-radical biochemistry in cancer etiology and treatment. She completed her MA and Ph.D. degrees at The Ohio State University, where she trained in immunology and microbiology.

Dr. George Poste, Ph.D., DVM

Dr. George Poste is the Del E. Webb Professor of Health Innovation and Chief Scientist, The Complex Adaptive Systems Initiative (CASI) ( at Arizona State University (ASU). This program integrates research in genomics, synthetic biology and high performance computing to study the altered regulation of molecular networks in human diseases to develop new diagnostic tests for precision (personalized) medicine and the remote monitoring of health status using miniaturized body sensors and mobile devices. He assumed this post in 2009. From 2003 to 2009 he directed and built The Biodesign Institute at ASU. He has published more than 350 research papers and edited 14 books on pharmaceutical technologies, cancer and infectious diseases. He has received honorary degrees in science, law and medicine for his research contributions. He serves on the Board of Directors of Monsanto, Exelixis, Caris Life Sciences, and the Scientific Advisory Boards of the A. Alfred Taubman Medical Research Institute at the University of Michigan, Synthetic Genomics, and Haplogen GmbH. From 1992 to 1999, he was Chief Science and Technology Officer and President, R&D, of SmithKline Beecham (SB). During his tenure at SB, he was associated with the successful registration of multiple drug, vaccine and diagnostic products. In 2004 he was named “R&D Scientist of the Year” by R&D Magazine, in 2006 he received the Einstein award from the Global Business Leadership Council, and in 2009 he received the Scrip Lifetime Achievement award voted by the leadership of the global pharmaceutical industry. He is a Fellow of the U.K. Royal Society, the Royal College of Pathologists and the U.K. Academy of Medicine, a former Distinguished Fellow at the Hoover Institution, Stanford University, a member of the Council for Foreign Relations, a Governor of the Bulletin of Atomic Scientists, and a member of the U. S. Institute of Medicine Board on Global Health. He has served as a member of the Defense Science Board of the U.S. Department of Defense and currently serves on advisory committees for several U.S. government agencies in defense, intelligence, national security and healthcare.

Jacque Sokolov, M.D.

Dr. Sokolov is chairman and chief executive officer of SSB Solutions, Inc., a US based and diversified healthcare management, development and financial services company. Following his formal training as an academic cardiologist, Dr. Sokolov has had the opportunity to serve as board director, corporate officer and advisor, in multiple healthcare sectors including: Health Plans/Large Employers; Hospitals/Hospital Systems; Physician Practice Management Organizations/Group Practices; Clinically Integrated Organizations (CIOs/ACOs); Pharmaceutical Companies; Device Companies; Biotechnology Companies; and Private Equity/Venture Entities.  He started his career as Vice President for Healthcare and Chief Medical Officer for Southern California Edison Corporation (NYSE:EIX). Dr. Sokolov currently serves or has served in multiple board capacities for Public Companies including Hospira (NYSE:HSP), MedCath (NASDAQ:MDTH), and PhyAmerica (NYSE:ERDR); Private Companies including Veterans Accountable Care Group (VACG), GlobalMed, SMG Holding Company, MyHealthDirect, NeuLife Neurological Services, LLC (NeuLife), IntelaTrak, PCA Holdings and SSB Solutions/HCDG; and Non Profit Organizations including Phoenix Children’s Hospital, The Health Futures Council at ASU, The National Health Foundation, the American College of Medical Quality, the National Fund for Medical Education, the National Business Group on Health and the White House Health Project.

 Dr. Sokolov received his BA and MD Degree from the University of Southern California.  He completed his internal medicine residency at the Mayo Graduate School of Medicine and his fellowship in cardiovascular diseases from the University of Texas-Southwestern Medical School.  He previously held and currently holds academic appointments and advisory board responsibilities in the Schools of Medicine, Business and Public Health at Harvard, the Massachusetts Institute of Technology, the University of Pennsylvania, the University of California, Los Angeles, and the University of Southern California.